Pale Fire Capital SE’s enGene Therapeutics ENGN Stock Holding History

Pale Fire Capital SE’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$163K	Hold	24,004	–	–	0.01%	59
2025 Q4	$217K	Buy	24,004 +6,750	+39%	+$54.1K	0.01%	47
2025 Q3	$118K	Hold	17,254	–	–	0.01%	51
2025 Q2	$62.8K	Hold	17,254	–	–	0.01%	60
2025 Q1	$77.3K	Buy	17,254 +2,544	+17%	+$15.8K	0.01%	53
2024 Q4	$97.8K	Buy	+14,710	New	+$114K	0.02%	44

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Pale Fire Capital SE's ENGN Position: Q1 2026 in Review

Pale Fire Capital SE held its enGene Therapeutics (ENGN) position steady in Q1 2026 at 24,004 shares worth $163K. The position accounts for 0.01% of the portfolio, ranked #59.

Pale Fire Capital SE first reported a position in ENGN in Q4 2024 and has held it in 6 quarters since. The position peaked at $217K in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

Pale Fire Capital SE held 24,004 shares of enGene Therapeutics worth $163K as of Q1 2026.
Pale Fire Capital SE left its enGene Therapeutics share count unchanged in Q1 2026.
enGene Therapeutics made up 0.01% of Pale Fire Capital SE's portfolio in Q1 2026, its #59 holding.
Pale Fire Capital SE first reported a position in enGene Therapeutics in Q4 2024 and has held it in 6 quarters since.
Pale Fire Capital SE's enGene Therapeutics position peaked at $217K in Q4 2025.
61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Pale Fire Capital SE's 13F filing for Q1 2026, filed 14 May 2026.